Literature DB >> 17314138

Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models.

Benjamin Sredni1, Revital Geffen-Aricha, Wenzhen Duan, Michael Albeck, Frances Shalit, Harry M Lander, Noa Kinor, Ortal Sagi, Amnon Albeck, Sigal Yosef, Miri Brodsky, Dvora Sredni-Kenigsbuch, Tali Sonino, Dan L Longo, Mark P Mattson, Gal Yadid.   

Abstract

In Parkinson's disease (PD) dopaminergic neurons in the substantia nigra (SN) become dysfunctional and many ultimately die. We report that the tellurium immunomodulating compound ammonium trichloro(dioxoethylene-O,O'-)tellurate (AS101) protects dopaminergic neurons and improves motor function in animal models of PD. It is effective when administered systemically or by direct infusion into the brain. Multifunctional activities of AS101 were identified in this study. These were mainly due to the peculiar Tellur(IV)-thiol chemistry of the compound, which enabled the compound to interact with cysteine residues on both inflammatory and apoptotic caspases, resulting in their inactivation. Conversely, its interaction with a key cysteine residue on p21(ras), led to its activation, an obligatory activity for AS101-induced neuronal differentiation. Furthermore, AS101 inhibited IL-10, resulting in up-regulation of GDNF in the SN. This was associated with activation of the neuroprotective kinases Akt and mitogen-activated protein kinases, and up-regulation of the antiapoptotic protein Bcl-2. Inhibition of caspase-1 and caspase-3 activities were associated with decreased neuronal death and inhibition of IL-1beta. We suggest that, because multiple mechanisms are involved in the dysfunction and death of neurons in PD, use of a multifunctional compound, exerting antiapoptotic, anti-inflammatory, and neurotrophic-inducing capabilities may be potentially efficacious for the treatment of PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17314138     DOI: 10.1096/fj.06-7500com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  14 in total

1.  Multifunctional activity of a small tellurium redox immunomodulator compound, AS101, on dextran sodium sulfate-induced murine colitis.

Authors:  Gilad Halpert; Tom Eitan; Elena Voronov; Ron N Apte; Lea Rath-Wolfson; Michael Albeck; Yona Kalechman; Benjamin Sredni
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

2.  The anti-inflammatory effects of the tellurium redox modulating compound, AS101, are associated with regulation of NFkappaB signaling pathway and nitric oxide induction in macrophages.

Authors:  Miri Brodsky; Gilad Halpert; Michael Albeck; Benjamin Sredni
Journal:  J Inflamm (Lond)       Date:  2010-01-20       Impact factor: 4.981

3.  AS101 ameliorates experimental autoimmune uveitis by regulating Th1 and Th17 responses and inducing Treg cells.

Authors:  So Jin Bing; Itay Shemesh; Wai Po Chong; Reiko Horai; Yingyos Jittayasothorn; Phyllis B Silver; Benjamin Sredni; Rachel R Caspi
Journal:  J Autoimmun       Date:  2019-03-08       Impact factor: 7.094

4.  Ammonium trichloro [1,2-ethanediolato-O,O']-tellurate cures experimental visceral leishmaniasis by redox modulation of Leishmania donovani trypanothione reductase and inhibiting host integrin linked PI3K/Akt pathway.

Authors:  Preeti Vishwakarma; Naveen Parmar; Pragya Chandrakar; Tanuj Sharma; Manoj Kathuria; Pramod K Agnihotri; Mohammad Imran Siddiqi; Kalyan Mitra; Susanta Kar
Journal:  Cell Mol Life Sci       Date:  2017-09-12       Impact factor: 9.261

5.  Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha.

Authors:  Feifei Wang; Takao Yasuhara; Tetsuro Shingo; Masahiro Kameda; Naoki Tajiri; Wen Ji Yuan; Akihiko Kondo; Tomohito Kadota; Tanefumi Baba; Judith Thomas Tayra; Yoichiro Kikuchi; Yasuyuki Miyoshi; Isao Date
Journal:  BMC Neurosci       Date:  2010-04-26       Impact factor: 3.288

6.  The immunomodulator AS101 suppresses production of inflammatory cytokines and ameliorates the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Li Xie; Jing Chen; Anthony McMickle; Nadia Awar; Soad Nady; Benjamin Sredni; Paul D Drew; Shiguang Yu
Journal:  J Neuroimmunol       Date:  2014-06-07       Impact factor: 3.478

7.  Tellurium compound AS101 ameliorates experimental autoimmune encephalomyelitis by VLA-4 inhibition and suppression of monocyte and T cell infiltration into the CNS.

Authors:  Jun-Ho Lee; Meital Halperin-Sheinfeld; Dolgar Baatar; Mohamed R Mughal; Hyun-Jin Tae; Jie-Wan Kim; Arnell Carter; Ana Lustig; Omri Snir; Gad Lavie; Eitan Okun; Mark P Mattson; Benjamin Sredni; Dennis D Taub
Journal:  Neuromolecular Med       Date:  2013-11-23       Impact factor: 3.843

8.  The Tellurium compound, AS101, increases SIRT1 level and activity and prevents type 2 diabetes.

Authors:  Meital Halperin-Sheinfeld; Asaf Gertler; Eitan Okun; Benjamin Sredni; Haim Y Cohen
Journal:  Aging (Albany NY)       Date:  2012-06       Impact factor: 5.682

Review 9.  Metalloid compounds as drugs.

Authors:  B S Sekhon
Journal:  Res Pharm Sci       Date:  2013-07

10.  Novel microwave-assisted synthesis of the immunomodulator organotellurium compound ammonium trichloro(dioxoethylene-O,O')tellurate (AS101).

Authors:  M Pilar Vázquez-Tato; Alberto Mena-Menéndez; Xesús Feás; Julio A Seijas
Journal:  Int J Mol Sci       Date:  2014-02-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.